Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01232114
Other study ID # CB523002
Secondary ID
Status Recruiting
Phase N/A
First received October 19, 2010
Last updated November 1, 2010
Start date October 2010
Est. completion date October 2010

Study information

Verified date October 2010
Source Hunan University of Traditional Chinese Medicine
Contact Cai g xian, Master
Phone 8673188458001
Email lby1203@sina.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Observational

Clinical Trial Summary

Functional dyspepsia (FD) is a common functional gastrointestinal disorder and is steadily becoming a public health problem.Simotang is a classical formula that has been used to treat gastrointestinal disorders for hundreds of years [9] and was approved as an oral liquid drug by the Chinese National Food and Drug Administration in the 1980s.In this study,patients with functional dyspepsia were divided according to the inclusive criteria into treatment group and control group randomly, who were given Simo decoction or Domperidone tablets for 14 days。And then the gastric emptying, Symptoms in plasma were observed before and after treatment in mult-center.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date October 2010
Est. primary completion date October 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- patients met the definition of the Rome III criteria for FD

Exclusion Criteria:

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Dyspepsia
  • Effect of Simotang on FD Was Studied
  • Functional Dyspepsia(FD) Was Studied
  • Gastritis

Locations

Country Name City State
China Hunan university of TCM Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Hunan University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of gastrointestinal Symptom as efficacy and the Number of Participants with Adverse Events as a Measure of Safety 14 days Yes
Secondary Chinese version of the Nepean Dyspepsia Index as a Measure of efficacy 30 days No